Home » Astellas Still Wants CV Therapeutics
Astellas Still Wants CV Therapeutics
Astellas Pharma said it will continue to pursue a purchase of CV Therapeutics after the Palo Alto, Calif.-based drugmaker rejected Astellas’ $1 billion offer.
TheStreet.com
TheStreet.com
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May